Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Sinopharm

CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough

Drugmaker CSPC Pharma gets the green light to produce China’s first homegrown mRNA vaccine, but the breakthrough comes too late in the pandemic to impress investors Key Takeaways: News of…
March 29, 2023
1093.HK

YSB’s B2B Pharma Platform: Sexier Than the SOEs, But Stodgier Than B2Cs

The drug distributor for pharmacies and community-level medical institutions has filed for a Hong Kong listing, boasting strong revenue growth but also massive losses Key Takeaways: YSB has filed for…
May 31, 2022

CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

The company’s Convidecia has received emergency-use authorization from the World Health Organization, becoming the third Chinese vaccine to get that nod Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted…
May 26, 2022

AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt

Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
April 18, 2022
B.US

Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field

Global agreement for oral anti-viral comes just months after company signed separate similar tie-up for a Covid mRNA vaccine also in development Key Takeaways Everest has signed a global licensing…
January 20, 2022

Everest Joins Race to Make mRNA Covid Vaccines for China

Company’s move comes as Beijing shows growing signs of approving the new type of high-tech vaccination Key takeaways: Everest will pay up to $150 million or more to potentially bring…
September 21, 2021

Recent Articles

March 29, 2023

CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough

1093.HK
May 31, 2022

YSB’s B2B Pharma Platform: Sexier Than the SOEs, But Stodgier Than B2Cs

May 26, 2022

CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

April 18, 2022

AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt

B.US
January 20, 2022

Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field

September 21, 2021

Everest Joins Race to Make mRNA Covid Vaccines for China

RELATED ARTICLES

  1. Everest makes mRNA vaccines
    March 25, 2025
    Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  2. March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  3. April 3, 2025
    Dispute over Covid vaccines casts doubt on Clover Bio recovery
    2197.HK
  4. January 20, 2025
    Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
    ZYBT.US
  5. January 16, 2025
    WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.